US OptionsDetailed Quotes
SPRY250516C17500
- 0.20
- -0.25-55.56%
15min DelayClose Apr 28 16:00 ET
0.20High0.15Low
0.15Open0.45Pre Close17 Volume163 Open Interest17.50Strike Price265.00Turnover85.85%IV25.18%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.1548Delta0.0886Gamma70.70Leverage Ratio-0.0180Theta0.0010Rho10.95Eff Leverage0.0075Vega
ARS Pharmaceuticals Stock Discussion
Sign in to post a comment
$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray designed for emergency treatment of Type I allergic reactions, including anaphylaxis. Below is an analysis of SPRY stock based on available data as of March 17, 2025:
### Company Overview
- Product: Neffy is the first FDA-approved needle-free epinephrine delivery system, offering an al...
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray designed for emergency treatment of Type I allergic reactions, including anaphylaxis. Below is an analysis of SPRY stock based on available data as of March 17, 2025:
### Company Overview
- Product: Neffy is the first FDA-approved needle-free epinephrine delivery system, offering an al...
6
1
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
34
7
$ARS Pharmaceuticals (SPRY.US)$ Reuters
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to
5
$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...
1
$ARS Pharmaceuticals (SPRY.US)$
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
3
2
$ARS Pharmaceuticals (SPRY.US)$ Showcases Intranasal Epinephrine Data At 2024 American College Of Allergy, Asthma & Immunology Annual Scientific Meeting, Friday October 25.
No comment yet
mohd ammi bin ismail : hello